Physician profile
Michael A Davis
NPI 1578940987
$6,258.45
in general payments reported to CMS, 2019-2025
46 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $1,094 · 2021: $1,372 · 2022: $826 · 2023: $830 · 2024: $735 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,495.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $681.25 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $601.42 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $392.05 | 2019-2025 | |
| Lilly USA, LLC | $349.38 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $308.73 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $302.02 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.23 | 2019-2023 | Jardiance |
| Abbott Laboratories | $152.82 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $148.76 | 2019-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.96 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $143.10 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $139.49 | 2019-2022 | |
| Amarin Pharma, INC. | $121.62 | 2019-2021 | |
| Irhythm Technologies, INC. | $117.92 | 2024 | Zio Xt Patch, Zio Monitor |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.